Please login to the form below
diabetic macular edema
This page shows the latest diabetic macular edema news and features for those working in and with pharma, biotech and healthcare.
FDA approves Coherus’ Cimerli as biosimilar interchangeable with Lucentis for all five indications
Cimerli is interchangeable for retinal indications including neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy and myopic choroidal neovascularisation.
Latest news
-
Roche’s Vabysmo recommended for EU approval by CHMP for sight loss
with neovascular macular degeneration (nAMD) and visual impairment caused by diabetic macular edema (DME).
-
Eylea growth closes the gap with Lucentis
Armed with new indications such as diabetic macular edema (DME), Eylea (aflibercept) can now compete with rival Lucentis (ranibizumab) sold by Roche and Novartis on a more equal footing and sales ... visual impairment due to macular oedema resulting from
-
Fresh approval for Roche's Lucentis as competition heats up
drug. Lucentis (ranibizumab) has become the first medicine in the US to be cleared to treat diabetic retinopathy in people with diabetic macular edema (DME), which affects around 750, 000 Americans ... Lucentis' approval "gives patients with diabetic
-
Bayer files Eylea for diabetes complication in EU
Looks to keep with Novartis’ Lucentis. Bayer is trying to win approval for a third indication for its big-selling eye disease treatment Eylea, namely the treatment of diabetic macular edema ... DME). Eylea (aflibercept) - also known as VEGF Trap-Eye -
-
Lucentis cleared in Europe for pathological myopia
Lucentis was originally developed by Genentech - which has US marketing rights - and is already approved for the treatment of wet age-related macular degeneration (AMD), diabetic macular edema (DME) and macular ... edema secondary to retinal vein
More from news
Approximately 1 fully matching, plus 11 partially matching documents found.
Latest Intelligence
-
Deal Watch June 2016
in development for diabetic macular edema (DME) and uveitis.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Country Manager, Healthcare Communications Agency, Germany
-
Highly competitive salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- AstraZeneca and Innate Pharma to end study on immuno-oncology drug monalizumab
- AstraZeneca and MSD’s breast cancer drug Lynparza receives EC approval
- Regeneron terminates four clinical trials of its COVID-19 antibody cocktail REGEN-COV
- Roche’s Tecentriq demonstrates positive phase 3 results as a subcutaneous injection
- Gilead announces positive Biktarvy data for HIV and hepatitis B
- Janssen announces positive results supporting Rybrevant and lazertinib combination treatment for NSCLC
- Medscape Education Receives Joint Accreditation with Commendation to Deliver Continuing Education for Healthcare Providers
- Amgen acquires ChemoCentryx in $3.7bn cash deal
- Gilead Sciences set to acquire MiroBio in deal worth over $400m
- NHS England to roll out continuous glucose monitors to all those with type 1 diabetes
- Sanofi and Innovent Biologics to develop oncology drugs for patients in China
- WHO launches funding appeal for greater Horn of Africa prompted by food crisis
PMHub
Anthill Agency
Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...
Latest intelligence
- Animation: Living With
- The journey from the patient's perspective...
- Achieving communication excellence by targeting the right channel at the right time
- By Danny Buckland...
- 6 trends shaping the future of personalized medicine
- Senior Consultant Leah Carlisle explores the key trends discussed at the 16th annual Personalized Medicine Conference, providing expert analysis and key recommendations for biopharmaceutical innovators....
